181 related articles for article (PubMed ID: 35326583)
1. Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in
Stegel V; Blatnik A; Škof E; Dragoš VŠ; Krajc M; Gregorič B; Škerl P; Strojnik K; Klančar G; Banjac M; Žgajnar J; Ravnik M; Novaković S
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326583
[TBL] [Abstract][Full Text] [Related]
2. Germline and Somatic
You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
Front Oncol; 2020; 10():295. PubMed ID: 32211327
[No Abstract] [Full Text] [Related]
3. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
[TBL] [Abstract][Full Text] [Related]
4. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
5. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
6. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
[TBL] [Abstract][Full Text] [Related]
7. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
Dumbrava EI; Brusco L; Daniels M; Wathoo C; Shaw K; Lu K; Zheng X; Strong L; Litton J; Arun B; Eterovic AK; Routbort M; Patel K; Qi Y; Piha-Paul S; Subbiah V; Hong D; Rodon J; Kopetz S; Mendelsohn J; Mills GB; Chen K; Meric-Bernstam F
JCO Precis Oncol; 2019; 3():. PubMed ID: 31517177
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
[TBL] [Abstract][Full Text] [Related]
9. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
10. Somatic variants of potential clinical significance in the tumors of
Buckingham L; Mitchell R; Maienschein-Cline M; Green S; Hu VH; Cobleigh M; Rotmensch J; Burgess K; Usha L
Hered Cancer Clin Pract; 2019; 17():21. PubMed ID: 31346352
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
Duan RR; Sun LX; Zhao HW
Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
[No Abstract] [Full Text] [Related]
12. Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection.
Paradiso AV; Patruno M; Digennaro M; Tommasi S; Pilato B; Argentiero A; Brunetti O; Silvestris N
Front Oncol; 2020; 10():1292. PubMed ID: 32903564
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of mutations in a diverse cohort of 3162 women tested via the same multigene cancer panel in a managed care health plan.
Alvarado M; Tiller GE; Chung J; Haque R
J Community Genet; 2020 Jul; 11(3):359-366. PubMed ID: 32096056
[TBL] [Abstract][Full Text] [Related]
14. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore.
Zhang Z; Ishak NDB; Que FVF; Chua ZY; Chan SH; Chiang J; Yie JNY
Hered Cancer Clin Pract; 2023 Apr; 21(1):5. PubMed ID: 37046302
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
17. Is Reflex Germline
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Schlecht H; Jayson GC; Evans DGR
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765687
[TBL] [Abstract][Full Text] [Related]
18. Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
Azzollini J; Vingiani A; Agnelli L; Tamborini E; Perrone F; Conca E; Capone I; Busico A; Peissel B; Rosina E; Ducceschi M; Mantiero M; Lopez S; Raspagliesi F; Niger M; Duca M; Damian S; Proto C; de Braud F; Pruneri G; Manoukian S
Front Oncol; 2022; 12():857515. PubMed ID: 35463374
[TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
20. Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Fumagalli C; Tomao F; Betella I; Rappa A; Calvello M; Bonanni B; Bernard L; Peccatori F; Colombo N; Viale G; Barberis M; Guerini-Rocco E
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
